Oncology
Refine Search
Biotechnology
Colorado, USA-based SomaLogic yesterday said it is adding to its list of collaborative agreements with Danish diabetes care giant Novo Nordisk. 29 June 2021
Biotechnology
Shares in USA-based CEL-SCI fell by almost half on Monday, following long-awaited results from a Phase III trial of Multikine (leukocyte interleukin), a novel kind of immunotherapy. 29 June 2021
Generics
Russian drugmakers continue to put a pressure on their global rivals operating in the local market, by the launch of production of generics of their original drugs, reports The Pharma Letter’s local correspondent. 29 June 2021
Biotechnology
At its June meeting, the European Medicines Agency’s human medicines committee (CHMP) recommended six novel medicines for approval, and issued a negative opinion on one. 26 June 2021
Biotechnology
The European Commission (EC) has approved Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) to treat locally advanced or metastatic basal cell carcinoma (BCC) patients who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI). 25 June 2021
Pharmaceutical
Leading PARP inhibitor Lynparza (olaparib) has secured conditional approval in China for certain people with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). 24 June 2021
Pharmaceutical
GlaxoSmithKline has sought to reassure investors of a bright future for what it is calling the New GSK following the planned demerger in mid-2022 of its Consumer Healthcare business. 24 June 2021
Generics
Indian drug major Sun Pharmaceutical Industries has settled the patent litigation over a generic version Revlimid (lenalidomide) in the USA. 24 June 2021
Biotechnology
Funds managed by Blackstone have committed $250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company. 23 June 2021
Biotechnology
Iksuda Therapeutics, a privately-held UK-based developer of antibody drug conjugates (ADCs) with raised therapeutic index, has expanded its research collaboration and license agreement with Korean biotech LegoChem Biosciences. 22 June 2021
Pharmaceutical
Chinese biopharma companies are eyeing strategic collaborations with western counterparts to leverage their extensive networks and commercial capabilities to promote indigenously developed drugs in China. 22 June 2021
Pharmaceutical
Skopinsky Pharmaceutical Plant, one of Russia’s leading pharmaceutical producers, has signed a memorandum with the local subsidiary of Swiss pharma giant Novartis on scientific and technological cooperation in the field of oncology, according to the partners. 22 June 2021
Pharmaceutical
French biotech Ethypharm, a specialist in central nervous system (CNS) disorders and critical care, is to buy Spanish firm Altan Pharma. 21 June 2021
Biotechnology
The European Commission (EC) has granted full Marketing Authorization for Onureg (azacitidine tablets; CC-486), US pharma major Bristol Myers Squibb announced on Friday. 21 June 2021
Biotechnology
Japan’s Daichi Sankyo last Monday gained approval to market its malignant glioblastoma candidate, Delytact (teserpaturev) on the domestic market. USA-based Novavax released new Phase III data on its COVID-19 vaccine, giving the firm a leg up in the development program. Belgian biotech iTeos Therapeutics signed a collaboration deal for its anti-TIGIT candidate EOS-448 with UK pharma major GlaxoSmithKline, potentially worth more than $2 billion. US biotech Biogen last Monday released disappointing Phase III results for its investigational rare eye disease drug timrepigene emparvovec. Last Wednesday, the US Food and Drug Administration granted approval for Blueprint Medicines’ Ayvakit as a treatment for systemic mastocytosis. 20 June 2021
Biotechnology
Japanese drug major Eisai’s shares closed up 6% at 12.075 yen today, as it revealed an exclusive global agreement with the USA’s Bristol Myers Squibb for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC), that could earn the company more than $3 billion. 18 June 2021
Biotechnology
Gilead Sciences’ subsidiary has announced a strategic partnership with privately held US biotech Shoreline Biosciences to develop novel cell therapies across a variety of cancer targets. 18 June 2021
Biotechnology
The US Food and Drug Administration approved Cambridge, Massachusetts-based Blueprint Medicines’ Ayvakit (avapritinib) for adult patients with advanced systemic mastocytosis (AdvSM). 17 June 2021
Biotechnology
Independent private equity firm Jeito Capital, which is dedicated to biotech and biopharma, today announced that it has become a key investor as part of a $67 million Series B financing round in Alentis Therapeutics. 15 June 2021
Biosimilars
South Korean biosimilars specialist Celltrion Healthcare has presented new Phase IV data for Truxima (rituximab-abbs) at the annual meeting of the European Hematology Association (EHA). 14 June 2021
Biotechnology
Research news last week included US biotech releasing early data for its FT819 in the treatment of systemic lupus erythematosus (SLE), which sent the firm’s shares leaping as much as 70%. Also, Netherlands-based NewAmsterdam Pharma announced positive data on its obicetrapib and ezetimibe combination in cardiovascular disease. On the regulatory front, Dutch firm argenX and China’s Zai Lab gained approval from the Chinese medicines regulator for their Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP) care. Meantime, USA-based Kura Oncology signed a collaboration with Japan’s Kyowa Kirin on the development of ziftomenib for myeloid leukemia (ALS). 24 November 2024
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze